– Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner – First of three planned Phase 3 MDD studies now initiated – Expanding ion channel portfolio includes Kv7 and Nav1.7 candidates advancing towards IND filings in 2025 VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to disco ...

VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025. Company Presentation Details: Date:Monday, January 13, 2025Time:9:45-10:25 AM Pacific ...

It has been about a month since the last earnings report for Xenon Pharmaceuticals (XENE) . Shares have added about 2.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Xenon Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Xenon Q3 Loss Narrower Th ...

VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 9:10 a.m. ET (webcast link)Jefferies London Healthcare Conference 2024 on Wednesday, November ...

Xenon Pharmaceuticals Inc. (XENE) reported a loss of 81 cents per share for the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 82 cents. The company had incurred a loss of 73 cents per share in the year-ago quarter.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences (NBIX) for XEN901, now known ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Caroline Pocher - JPMorgan Andrew Tsai - Jefferies Brian Abrahams - RBC Capital Markets Luke Herrmann - Baird Jason Gerberry - Bank of A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact n ...

Exhibit 99.1 HXENC Xenon Reports Q3 2024 Financial Results and Business Update – Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end – Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025 – Recent appointment of Matt Ronsheim, experienced pharmac ...

– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end – Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025 – Recent appointment of Matt Ronsheim, experienced pharmaceutical executive joining Xenon’s senior executive team as Chief Operating Offi ...

VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024. Conference Call/Webcast Information: Date: Tuesday, November 12, 2024  Time:4:30 pm Eastern Time (1 ...